News
CAMRF
55.00
NaN%
--
Camurus Boosts Share Count to Support Employee Incentive Plan
TipRanks · 06/30 05:34
Camurus hit by FDA manufacturing setback on U.S. acromegaly drug filing
TipRanks · 06/10 23:03
Camurus Targets Real‑World Evidence in New Acromegaly Study With Octreotide Depot
TipRanks · 06/04 16:32
Eli Lilly expands collaboration with Camurus to include amylin agonists
Seeking Alpha · 06/01 19:38
Camurus Wins Lilly Option Exercise, Extending Long-Acting Cardiometabolic Drug Deal
TipRanks · 06/01 15:53
Camurus Repurchases Series C Shares to Fund Long-Term Incentive Plan
TipRanks · 05/28 19:02
Camurus AGM Backs Board, Withholds Dividend and Approves New Performance Share Plan
TipRanks · 05/28 17:32
Camurus AB (publ) GAAP EPS of SEK2.40, revenue of SEK533M
Seeking Alpha · 05/12 13:52
Camurus Holds Course on 2026 Outlook Despite Softer Q1 Sales
TipRanks · 05/12 05:48
Camurus Targets Severe Diseases With Long-Acting Drug Innovations
TipRanks · 04/29 08:32
Camurus calls 2026 AGM with capital measures and new incentive plan on agenda
TipRanks · 04/24 06:43
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ), Zealand Pharma (OtherZLDPF) and Camurus AB (OtherCAMRF)
TipRanks · 04/16 12:21
Camurus Expands Share Capital After Employee Stock Option Exercises
TipRanks · 03/31 05:41
Camurus Expands Share Capital After Employee Stock Option Exercises
TipRanks · 02/27 15:34
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Medtronic (MDT) and Camurus AB (OtherCAMRF)
TipRanks · 02/18 12:20
Camurus Strengthens Executive Team With New Corporate Development Chief
TipRanks · 02/17 07:34
Camurus AB Earnings Call: Growth, FX and U.S. Push
TipRanks · 02/15 00:14
Camurus AB (publ) GAAP EPS of SEK1.67, revenue of SEK464M
Seeking Alpha · 02/12 20:08
Camurus Posts Strong 2025 Earnings, Expands Long-Acting Endocrine Portfolio
TipRanks · 02/12 06:35
Camurus announces FDA acceptance of NDA resubmission for Oclaiz
TipRanks · 01/09 14:40
More
Webull provides a variety of real-time CAMRF stock news. You can receive the latest news about Camurus Sweden through multiple platforms. This information may help you make smarter investment decisions.
About CAMRF
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.